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ABSTRACT
Background & Aims: An increase in Rho kinase (ROK) activity has been associated with the
agonist-induced sustained contraction of the smooth muscle, but its role in the pathophysiology
of spontaneously tonic smooth muscle is not known. Methods: Present studies examined the
effects of ROK inhibitor Y 27632 in the tonic smooth muscle of the rat internal anal sphincter
(IAS) vs. in the flanking phasic smooth muscle of the rectum (RSM). In addition, studies were
performed to determine the relationship between the decreases in the basal IAS tone vs. the ROK
activity. Confocal microscopic studies determined the cellular distribution of smooth muscle
predominant isoform of ROK (ROCK-II) in the smooth muscle cells (SMC). Results: In in vitro
studies using neurohumoral inhibitors and tetrodotoxin, and the use of SMC demonstrate direct
relaxation of the IAS SMC by Y 27632. The ROK inhibitor was more potent in the IAS than the
RSM. The IAS relaxation by Y 27632 correlated specifically with the decrease in ROK activity.
Confocal microscopy revealed high levels of ROCK-II towards the periphery of the IAS SMC.
In in vivo studies, the lower doses of Y 27632 caused a potent and selective fall in the IAS
pressures (IASP) without any adverse cardiovascular systemic effects. The ROK inhibitor also
caused potent relaxation of the hypertensive IAS. Conclusions: 1). RhoA/ROK play a crucial
role in the maintenance of the basal tone in the IAS; and 2). ROK inhibitors have a therapeutic
potential in the IAS dysfunction characterized by the hypertensive IAS.
Key Words: Smooth muscle tone; basal tone; phasic contraction; Rho kinase inhibitor;
RhoA/ROK
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INTRODUCTION
Disorders of the IAS underlie many clinical abnormalities, including fecal incontinence,1 and
constipation.2 Specifically, hypertensive IAS is associated with a number of gastrointestinal
disorders such as Hirschsprung’s disease,3-5 recurrent anal fissures and hemorrhoids.6,7
Knowledge of the molecular mechanisms that underlie control of the IAS smooth muscle tone is
essential to advance an understanding of the pathophysiology of these abnormalities and their
therapeutic management.
The IAS tone is largely maintained by the unique properties of the smooth muscle (SM)
proper.5,8 It has been suggested that the basal tone in other sphincteric smooth muscle may be
governed by Ca2+/MLCK or PKC pathways.9-11 Recently, it has been recognized that the smooth
muscle contraction in response to certain agonists occurs in two phases, an initial (phasic) and a
later sustained (tonic). Ca2+/MLCK is critical in the initial phase while RhoA/ROK plays a
major role in the sustained contraction.10,12,13
To date, a number of approaches have been suggested to treat rectoanal motility disorders
involving hypertensive IAS and incomplete relaxation. These are: Ca2+ channel blockers,14 NO
donors,15,16 botulinum toxin,17,18 and specific phosphodiesterase (PDE) inhibitors such as
Viagra.19,20 However, these approaches may lead to variable outcomes, prominent side effects
(especially cardiovascular hypotension), and desensitization. In addition, these approaches may
exert their final effects via other intracellular signal transduction pathways. For example, The
PDE inhibitors prevent the breakdown of cGMP,21 which in turn works via the inactivation of
RhoA/ROK.22
The defecation reflex (anorectal inhibitory reflex) is mediated via the sacral nerves that
impinge on the local myenteric nonadrenergic noncholinergic (NANC) inhibitory neurons
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(containing neuronal nitric oxide synthase or nNOS) within the IAS.4,5,23 The loss of such
neurons,4,24-26 may be associated with the hypertensive IAS and incomplete relaxation of the
IAS. Therefore, the agents that bypass the NOS/cGMP pathway, work directly in the SMC, and
have fewer systemic side effects, will be most desirable for the hypertensive IAS-associated
motility dysfunctions.
The purpose of the present investigation therefore, is to determine the role of RhoA/ROK as
the molecular bases for the genesis of basal tone in the IAS, and to explore ROK inhibitors as
therapeutic potentials for the hypertensive IAS. Y 27632 has been recognized to be a selective
ROK inhibitor both in vitro and in vivo settings.27
MATERIALS AND METHODS
Materials and methods
Measurement of Isometric Tension. Sprague-Dawley rats (300-350 g) were killed by
decapitation, and the anal canal with an adjacent region of the rectum was quickly removed and
transferred to oxygenated (95% O2/5% CO2) Krebs physiological solution (KPS) of the
following composition (mM): 118.07 NaCl, 4.69 KCl, 2.52 CaCl2, 1.16 MgSO4, 1.01 NaH2PO4,
25 NaHCO3, and 11.10 glucose (37ºC). Circular smooth muscle strips (~0.5 X 7 mm) of the IAS
and the rectal smooth muscle (RSM) were prepared as explained previously28 and transferred to
2-ml muscle baths containing oxygenated KPS at 37ºC. Isometric tension was measured via
force transducers (model FT03; Grass Instruments, Quincy, MA) using the PowerLab/8SP data-
acquisition system (AD Instruments, Australia) using Chart 5 (AD Instruments).29-31 The
changes in basal IAS tone were expressed as % of maximal relaxation by 10 mM EDTA at the
end of each experiment.32
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The experimental protocol of the study was approved by the institutional Animal Care and
Use Committee of Thomas Jefferson University and was in accordance with the
recommendations of the American Association for the Accreditation of Laboratory Animal Care.
Recording of Intraluminal Pressures of the IAS (IASP) and Mean Systolic Blood Pressure
(MSBP). The high pressure zone of the IAS was identified using slow station pull through, and
IASP were monitored by the modified approach of Terauchi et al.,33 using solid-state catheter
assembly (Millar Instruments, Houston, TX). For some studies, IASP were also monitored using
custom-designed water-perfused catheter assembly (Arndorfer Inc., Greendale, WI) that consists
of 25 cm long vinyl tube of three channels of a 0.3-mm inside and 0.6-mm outside diameter
each.
MSBP was recorded via a non-invasive blood pressure measurement system (by tail cuff
method) using computerized PowerLab/8SP data-acquisition system (AD Instruments).
Drug Responses. Concentration-response Curves (CRCs) for Y 27632 (1 nM to 100 µM) in the
IAS and RSM were obtained in a cumulative fashion. N-nitro-L-arginine (L-NNA) (300 µM),
neurotoxin tetrodotoxin (TTX) (1 µM), propranolol (1 µM), and hexamethonium (100 µM) were
added in the muscle bath as single doses 15 min before testing the effect of Y 27632. For in vivo
studies the effects of Y 27632 on IASP and MSPB were determined in doses ranging from 0.1 to
200 nmols/kg.
Preparation of Dispersed IAS Smooth Muscle Cells (SMC) and Measurement of Cell
Lengths. SMC were isolated from rat IAS and RSM by sequential enzymatic digestion, filtration
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and centrifugation as described previously.30 Briefly, the smooth muscle tissues were cut into
0.2 x 0.2 mm blocks and incubated in KPS containing 0.1% collagenase and 0.01% trypsin
inhibitor. The partly digested strips were washed, and muscle cells were allowed to disperse
spontaneously for 30 min. SMC were then harvested by filtration through 500 µM Nitex mesh
and centrifuged twice at 350 g for 10 min. 104 cells in 100 µL KPS were treated with 20 µL of a
solution containing the test agents. The reaction was interrupted at 5 min by the addition of 0.1
ml acrolein at a final concentration of 1%. Individual cell length was measured by computerized
image microscopy. The average length of cells in the control state or after addition of test agents
was obtained from 50 cells encountered randomly in successive microscopic fields.
Rho kinase (ROK) and PKC Activity Assays. While monitoring the isometric tension, the rat
RSM and IAS smooth muscle strips were quick-frozen in the basal state, and following the
pretreatments with Y 27632 and Gö 6850. The tissues were put into liquid N2 immediately and
stored at -80ºC. Later, the respective tissues were cut into small pieces and homogenized in
homogenization buffer (in a volume equal to 5 times the weight). The composition of the
homogenization buffer was: 50 mM Tris-HCl, pH 7.5; 5 mM EDTA; 10 mM EGTA; 1 mM
phenylmethylsulfonyl fluoride; 10 mM benzamide; 0.3% w/v 2-mercaptoethanol). The
homogenates were centrifuged (14,000 rpm) for 5 min and supernatants were collected. Protein
concentration in resultant supernatants was determined by the method of Lowry et al.,34 using
bovine serum albumin (BSA) as a standard (Pierce). 25 µg of proteins in 10 µl of lysate were
used for kinase assay.
For the ROK activity assay, tissue lysates were mixed with 30 µM Long S6 kinase substrate
peptide (Upstate, Lake Placid, NY). Kinase assays were initiated by the addition of 10 µCi of [-
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32P]ATP (3000 Ci/mmol) (Amersham Biosciences Corp, Piscataway, NJ) and 100 µM ATP,
followed by incubation for 10 min at 30ºC. [32P]substrate peptide was absorbed onto P81
Whatman phosphocellulose discs (Fisher), and free radioactivity was removed by repeated
washings with 75 mM phosphoric acid. The amount of radioactivity on the discs was measured
by liquid scintillation. The results were expressed as CPM/min/mg protein.12,22
PKC activity was determined using the PKC assay kit (Upstate, Lake Placid, NY). Briefly
tissue lysates were mixed with 80 µM PKC substrate peptide [QKRPSQRSKYL] (Upstate), 0.1
mg/ml phosphatidyl serine and 0.01 mg/ml diacylglycerol. Kinase assays were initiated by the
addition of 10 uCi of [ - 32P]ATP (3000 Ci/mmol) (Amersham) and 100 uM ATP, followed by
incubation for 10 min at 30ºC. [32P]substrate peptide radioactivity was determined as explained
above. The results were expressed as percentage of the basal activity in the IAS.12
Western Blot Analysis of ROCK-II, and Measurement of Free Intracellular Ca2+ [Ca2+]i
Levels. ROCK-II is considered to be the primary isoform of ROK involved in the RhoA/ROK-
related pathway in the smooth muscle contraction. Levels of ROCK-II were determined using
Western blot analysis. For this, first, tissue lysates of the IAS and RSM and protein extracts
were prepared as described before.29-31 Then, 20 µg of proteins were separated by 7.5% SDS-
PAGE and electrophoretically transferred onto a nitrocellulose membrane (NCM). The NCM
was soaked overnight at 4ºC in Tris-buffered saline with Tween (TBS-T; composed of: 20 mM
Tris pH 7.6, 137 mM NaCl, and 0.1% Tween-20) containing 5% nonfat dry milk. The NCM was
then incubated with the primary antibodies diluted in TBS-T containing 1% milk (1:1000 for
ROCK-II and 1:20,000 for -actin) for 1h at room temperature. After washing with TBS-T three
times, the NCM was incubated with the horseradish peroxidase conjugated species-specific
secondary antibody. The NCM was washed with TBS-T and the corresponding bands were
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visualized with enhanced chemiluminescence substrate using the SuperSignal® West Pico
Chemiluminescent Substrate (Pierce, Rockford, IL) and captured on X-ray film. Bands
corresponding to different proteins on X-ray films were scanned and their relative densities
determined by using Image-Pro Plus 4.0 software (Media Cybernetics).
[Ca2+]i levels of the IAS smooth muscle strips were measured using a JASCO calcium
analyzer (model CAF-100, JASCO, Inc., Easton, MD) using Fura-2 AM (Molecular Probes,
Eugene, OR) as the fluorescent indicator, following the method of Grynkiewictz et al.,35 with
specific modifications.36 Rmin and Rmax were determined by treating the tissues with EGTA (3
mM) and Triton X-100 (0.4%), respectively, at the end of each experiment.
Confocal Microscopy. The SMC were cultured in DMEM medium with 10% fetal bovine
serum, 5% penicillin-Streptomycin, 50 µg/ml gentamycin, and 2 µg/ml Amphotericin B on Lab-
Tek II chamber slides (Nulge Nunc International, Naperville, IL) at 37oC and 5% CO2 in an
incubator with humidity. At confluence, culture medium was removed and the cells were fixed
in 4% paraformaldehyde solution in DPBS at room temperature for 15 min. SMC were washed
three times with DPBS and incubated overnight at room temperature in a humid environment
with 1:100 dilution of ROCK-II primary antibody (raised in rabbit) (Santa Cruz Biotechnology
Inc., Santa Cruz, CA) in DPBS containing 0.2% Triton X-100 and 0.5% BSA. SMC were
washed three times with DPBS and incubated with Texas red-conjugated anti-rabbit secondary
antibody (1:200) (Santa Cruz) and FITC-conjugated -actin antibody (1:800) (Sigma) in DPBS
with 0.3% Triton X-100 and 2% Donkey serum for 1 hr. SMC were then washed three times
with DPBS and chambers were removed from slides. The slides were air-dried and coverslips
were mounted on the slides using VECTASHIELD mounting medium (Vector Labs,
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Burlingame, CA). Florescence was analyzed with Bio-Rad MRC 600 laser scanning confocal
microscope (Zeiss Anxiovert 100, Overkochen, Germany). Texas Red was excited at 543 nm
with helium/neon laser and FITC was excited at 488 nm with argon laser. The fluorophores
were detected separately and overlay images were generated automatically by the imaging
software.
Data Analysis. Data are presented as means ± standard error for the number of animals
indicated. Western blot data were normalized to smooth muscle -actin (relative density).
When comparing two groups, an unpaired Student’s t test was used. CRCs were analyzed using
two way ANOVA test.
Drugs and Chemicals. Y 27632 was purchased from Calbiochem (San Diego, CA). ROCK-II
antibody was purchased from Santa Cruz biotechnology Inc. (Santa Cruz, CA). -actin
antibody, L-NNA, tetrodotoxin (TTX), propranolol, and hexamethonium chloride were obtained
from sigma (St. Louis, MO). Gö 6850 (bisindolylmaleimide I) was obtained from Tocris
(Ellisville, MO). L-NNA, TTX, propranolol, and hexamethonium chloride were dissolved in
distilled water.
RESULTS
Effect of Y 27632 on the Basal Tone of the IAS vs. the Phasic Activity of the Rectal Smooth
Muscle (RSM). The ROK inhibitor caused a concentration-dependent fall in the basal tone of
the IAS (Figure 1) with ~30 fold higher potency than in the phasic smooth muscle of the RSM.
EC50 in causing the fall in the IAS tone vs. in the phasic activity of the RSM were 0.44 µM and
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13 µM, respectively. Y 27632 (1 µM) caused 50% inhibition (IC50) in the basal IAS tone
without a significant effect in the RSM. Typical tracings of the effects of Y 27632 in the IAS
and RSM are shown in Figure 2, panels A and B, respectively.
Effect of Y 27632 on Internal Anal Sphincter Pressure (IASP) and Mean Systolic Blood
Pressure (MSBP). Similar to the fall in the basal IAS tone in in vitro studies, the ROK inhibitor
also caused fall in the IASP in a dose-dependent manner (Figure 3). In this regard, 1 and 10
nmol/kg caused 37.5 ± 5.2% and 71.0 ± 7.7% fall in the IASP, respectively. Similar doses of the
inhibitor caused a minimal fall in the MSBP of 0.8 ± 0.6% and 11.4 ± 4.7%, respectively. Y
27632 was ~200 times more potent in causing a fall in the IASP as compared to the fall in the
MSBP.
Influence of Neurotoxin Tetrodotoxin (TTX) and Neurohumoral Inhibitors on Y 27632-
Induced Fall in the Basal IAS Tone. TTX (1 µM), hexamethonium (100 µM), and -
adrenoceptor blocker propranolol (1 µM) had no significant effect on Y 27632-induced fall in
the basal IAS tone (p > 0.05; n = 5-7; Figure 4A). Consistent with these data, the fall in the IAS
tone by the ROK inhibitor was also not modified by the NOS inhibitor L-NNA (300 µM) (p >
0.05; n = 5-7). These data suggest that Y 27632 causes a fall in the IAS tone by its effect
directly at the SMC.
Effect of Y 27632 on the Isolated Smooth Muscle Cells (SMC) of the IAS vs. the RSM.
Direct effect of the ROK inhibitor on the IAS SMC was confirmed by the concentration-
dependent relaxation of the SMC isolated from the IAS (Figure 4B). In this regard, 10 µM Y
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27632 caused maximal relaxation (37.8 ± 4.4 %) of the IAS SMC, and had no significant effect
on the lengths of SMC from the RSM (n = 4 animals). Not shown data similar to the effect of Y
27632 was obtained with another ROK inhibitor H 1152 in the IAS smooth muscle and the SMC.
Comparison of ROK activity in the IAS vs. RSM in the Basal State and Following Y 27632.
Actual levels of ROK activity were found to be significantly higher in the IAS vs. RSM (*; p <
0.05; n = 4; Figure 5A). There was a close relationship between the fall in the IAS tone and the
decrease in ROK activity in the presence of different concentrations of Y 27632 (1nM to 10 µM)
(Figure 5B) (r2 = 0.95). 1 µM of Y 27632 caused 50.1 ± 3.3 and 45.8 ± 2.2% decrease in the
IAS tone and in the ROK activity, respectively. On the contrary, 1 µM Gö 6850 (PKC inhibitor)
caused no significant change in the basal ROK activity in the IAS (97.4 ± 7% vs. 100% of the
basal state) (p > 0.05; n = 4). These data provide further evidence in favor of role of RhoA/ROK
in the basal tone in the IAS.
Western blot analysis of ROCK-II revealed significantly higher levels of ROCK-II in the IAS
as compared with the RSM (*; p < 0.05; n = 4; Fig. 5C).
The fall in the IAS tone following the ROK inhibitor was not related to either the changes in
[Ca2+]i or the PKC activity (p > 0.05; n = 4; Figure 6).
Presence of ROCK-II in the SMC of the IAS. To determine the cellular localization of
ROCK-II, we performed confocal microscopy studies. The data revealed significantly higher
levels of RhoA and ROCK-II towards the periphery of the IAS SMC as compared to those of the
RSM (data is shown only with ROCK-II in the IAS SMC; Figure 7). Data further show that the
ROK inhibitor caused the redistribution of ROCK-II to the inside of the cells. These data
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suggest that in the basal state, RhoA/ROK remain in active state to maintain basal tone in the
IAS.
Effect of Rho Kinase Inhibitor in the Hypertensive IAS. In order to determine the clinical
relevance of RhoA/ROK and the inhibitor, we investigated the effect of Y 27632 in the
hypertensive IAS. For this, we used the rat model of IAS in the presence of NOS inhibitor L-
NNA (300 µM). This treatment mimicked the symptoms of segmental Hirschsprung’s disease,
elevated IAS tone and incomplete IAS relaxation.5 In these experiments, L-NNA increased the
IAS tone from 0.7 ± 0.07 g to 1.2 ± 0.08 g (n = 5), and nearly obliterated the NANC relaxation.
In the hypertensive IAS Y 27632 caused a concentration-dependent fall in the IAS tone (Figure
8), and this fall was significantly greater with 3x10-7 and 1x10-6 M (*; p < 0.05; n = 5). Data
suggest the potential use of ROK inhibitors in the hypertensive IAS. Not shown, similar data
were obtained in in vivo studies.
DISCUSSION
The studies show that the basal tone in the IAS is critically dependent on RhoA/ROK.
Selectivity and potency of the ROK inhibition in causing IAS relaxation without significant side
effects, and its effectiveness in the hypertensive IAS suggest a therapeutic potential of this
approach in certain conditions associated with the hypertensive IAS.
The relaxant effect of ROK inhibition works directly at the SMC due to the lack of effect of
different neurohumoral inhibitors and the neurotoxin TTX, and by the demonstration of the
effects in the SMC. It is well known that NO is the major inhibitory mediator of the IAS
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relaxation in response to NANC nerve stimulation.5,23,28,37 However, RhoA/ROK-mediated
smooth muscle relaxation of the IAS is independent of the NOS pathway since the NOS inhibitor
L-NNA failed to modify this effect.
RhoA/ROK are known to be present throughout the SMC, and during the sustained phase of
the contraction they translocate to the periphery of the SMC for the ROK activation.38,39 Once
activated, ROK inhibits MLC-phosphatase (MLCP) either directly or via phosphorylation of
CPI-17 (P-CPI-17). ROK-mediated MLCP inhibition decreases dephosphorylation of
phosphorylated-MLC20 (P-MLC20) and is responsible for the maintenance of sustained
contraction of the smooth muscle. This information from the existing literature only comes from
studies that use various agonists to induce smooth muscle contraction. This concept has never
been tested in the spontaneously tonic smooth muscles (such as the IAS).
Present studies show that the IAS relaxation as a result of ROK inhibition by Y 27632 is
selective and several fold potent as compared with the RSM. There is a direct relationship
between the changes in the IAS tone and ROK activity. In addition, the PKC inhibitor Gö 6850
does not modify the basal activity of ROK in the IAS. The presence of higher levels of
RhoA/ROK in the periphery of the IAS SMC (in contrast to the RSM SMC) was demonstrated
by actual ROK activity, and by direct visualization of ROCK-II via confocal microscopy.
ROCK-II is also present in higher levels in the IAS than in the RSM at the translational levels as
shown by Western blot analysis (Figure 5C). Data suggest that RhoA/ROK translocation is
highly selective and is characteristic of the IAS SMC in the basal state. In addition, our
preliminary studies suggest that pretreatment of the IAS SMC with constitutively active RhoA
mutant (RhoAV14)22 causes an increase in the ROK activity and shortening of the SMC (data not
shown). The ROK inhibitor was found to be selective in its mechanism of action since it does
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not affect the basal levels of [Ca2+]i and PKC activity.
Taken together, the data suggest that RhoA/ROK play a critical role in the maintenance of
basal tone in the IAS. Increase in the [Ca2+]i and MLCK activity may be important in the initial
(phasic) contraction of smooth muscle rather than in the maintenance of tone. PKC has been
speculated to play a role in the tonic contraction of certain smooth muscles,10,13 however its exact
role in the basal tone of the IAS is not known. A part of PKC-mediated effect is dependent on
MLCP inhibition via P-CPI-17, which also is one of the mechanisms of action of RhoA/ROK as
stated above.39 Whether or not there is any overlap between these events is not known.
RhoA/ROK have been suggested to play an important role in the etiology and in the therapy
of cardiovascular hypertension.40 The role of RhoA/ROK upregulation in the hypertensive IAS
or in the hypermotility of other gastrointestinal smooth muscles has not been investigated. A
hypertensive IAS accompanied by inadequate relaxation is a prominent pathophysiological
finding of Hirschsprung’s disease, hemorrhoids and anal fissures.5,15,41
The therapeutic potential of ROK inhibitor in the IAS dysfunction associated with the
hypertensive IAS is important from two standpoints. Firstly, as shown by the present data, such
agents cause IAS relaxation independent of the NOS/cGMP pathway since relaxation still
remains intact in the presence of NOS inhibition. It is thought that one of the underlying causes
of the sphincteric smooth muscle hypertension may be the lack of NOS-containing myenteric
inhibitory neurons.3,26,33,42 Consequently, an agent that causes relaxation via NOS pathway is
less likely to succeed in treating the IAS dysfunction. Secondly, other smooth muscle relaxants
may cause undesirable cardiovascular hypotension. Present studies further demonstrate that the
doses of ROK inhibitor causing near maximal fall in the IASP have no significant effect on the
cardiovascular system.
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Inhibitors of PDE5 (that selectively inhibit cGMP PDE) such as sildenafil (Viagra) have been
studied for the symptomatic relief of these conditions with variable results and undesirable side
effects.19,43 The successful effect of the PDE inhibitors relies on the inhibition of cGMP
breakdown causing an increase in the cGMP levels.43 According to recent studies, the effect of
cGMP, in turn, depends on ROK inactivation.22,44 ROK inhibitors (that cause direct and potent
relaxation of the smooth muscle) may have wide therapeutic implications in the hypermotility of
the gastrointestinal tract.
To examine the clinical relevance of ROK inhibition, we used a hypertensive IAS model
characterized by an increase in the IAS tone and incomplete NANC relaxation similar to the
Hirschsprung’s disease in humans.5,37,45 We determined that Y 27632 causes potent relaxation in
this model. Therefore, the present studies may have clinical utility in treatment of anorectal
motility disorders characterized by the hypertensive IAS.
From the data we conclude the basal tone in the IAS and perhaps other smooth muscle
sphincters is critically dependent upon RhoA/ROK. The selectivity and potency of the ROK
inhibition in causing IAS relaxation (free of side effects), and its effect in the hypertensive IAS,
suggest a therapeutic potential of this approach in conditions such as Hirschsprung’s disease and
perhaps in other spastic GI motility disorders.
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FIGURE LEGENDS
Figure 1. Effect of Y 27632 in the internal anal sphincter (IAS) vs. the rectal smooth muscle
(RSM). Considering the EC50 values, Rho kinase inhibitor was 30 times more potent in the IAS
vs. RSM (*; p < 0.05; n = 5).
Figure 2, A and B, typical tracings of the effect of Y 27632 in the IAS and RSM, respectively.
The ROK inhibitor causes concentration-dependent fall in the IAS tone and phasic contractions
of the RSM. However, the ROK inhibitor was several fold more sensitive in the IAS vs. the
RSM.
Figure 3. In in vivo studies to show that the in the lower dose range Y 27632 causes significant
fall in the intraluminal pressures in the IAS (IASP) (*; p < 0.05; n = 4) without significant effect
on the mean systolic blood pressure (MSBP). Considering the EC50 values, Y 27632 was ~200
times more potent in causing fall in the IASP vs. the MSBP. Maximal fall in the IASP was in
reference to the pressures in the rectum. Conversely, maximal fall in MSBP was in reference to
a possible fall of 60 mmHg; in the data shown, 200 nmol/kg of Y 27632 caused a fall of ~30
mmHg.
Figure 4. A. The neurohumoral inhibitors including the NOS inhibitor L-NNA have no
significant effect on the IAS relaxation caused by the ROK inhibitor (p > 0.05; n = 5-7). B. The
ROK inhibitor causes concentration-dependent and significant relaxation of the SMC from the
IAS (*; p < 0.05; n = 4) but no significant effect in the RSM SMC. Percent increase in the cell
length (in the presence of different concentrations of Y 27632) of the spontaneously contracted
SMC was calculated on the bases of original cell length. As pointed out in Methods section, in
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each case average length of cells was obtained from 50 cells in a random manner.
Figure 5. A. Comparison of ROK activity in the IAS vs. RSM reveals higher levels of the
activity in the IAS (*; p < 0.05; n = 4). B. Relationship between the decrease in the IAS tone and
in the ROK activity following different concentrations of ROK inhibitor. The comparison
reveals significant correlation between the two events (r2 = 0.95). C. Western blot analysis
demonstrates higher levels of ROCK-II protein expression in the IAS vs. the RSM (*; p < 0.05; n
= 4).
Figure 6. Effect of Y 27632 (10 µM) on free intracellular Ca2+ levels and PKC activity in the
IAS. Data shows that the ROK inhibitor has no significant effect on the levels of [Ca2+]i and
PKC activity (p > 0.05; n = 4).
Figure 7. Confocal microscopy showing the immunocytochemical localization of ROCK-II in
the SMC of the IAS. Data show higher levels of ROCK-II towards the periphery of the SMC
isolated from the IAS in the basal state (upper right panel). Pretreatment of the IAS SMC with Y
27632 causes redistribution of ROCK-II and relaxation of the SMC (lower right panel).
Figure 8. Effect of Y 27632 on the basal tone in the control and hypertensive IAS. The ROK
inhibitor causes relaxation of the IAS, and that in the submaximal concentrations, it causes
significantly higher relaxation in the hypertensive IAS (*; p < 0.05; n = 5).
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